2025-04-28 00:16:51
Latest Post
Tembo Global Industries Ltd. Wins Two Major Domestic Contracts Worth ₹51.82 Crores
Forbes Precision Tools and Machine Parts Ltd declares interim dividend of Rs. 5 for FY2025-26
NRB Bearings announces ₹200 Crore Capacity Expansion to Support Major European OEM Programs
SNL Bearings Ltd Q4 FY2024-25 PAT at Rs. 2.80 crore
Indraprastha Gas Ltd Q4 FY25 consolidated PAT climbs to Rs. 455.14 crores
Stock Report
Natco Pharma Ltd posts consolidated Q2FY24 PAT of Rs. 369 crores
Posted On : 2023-11-15 10:37:49( TIMEZONE : IST )
Natco Pharma Limited has reported Consolidated financial results for the period ended September 30, 2023.
Financial Results (Q2 FY2024) - QoQ Comparison
The company has reported total income of Rs. 1060.8 crores during the period ended September 30, 2023 as compared to Rs. 1160.2 crores during the period ended June 30, 2023.
The company has posted net profit / (loss) of Rs. 369 crores for the period ended September 30, 2023 as against net profit / (loss) of Rs. 420.3 crores for the period ended June 30, 2023.
The company has reported EPS of Rs. 20.60 for the period ended September 30, 2023 as compared to Rs. 23.26 for the period ended June 30, 2023.
| Financials | Q2 FY2024 | Q1 FY2024 | % Change |
| Total Income | ₹ 1060.8 crs | ₹1160.2 crs |  -8.57% |
| Net Profit | ₹369 crs | ₹420.3 crs | -12.21% |
| EPS | ₹20.60 | ₹23.26 | -11.44% |
Financial Results (Q2 FY2024) - YoY Comparison
The company has reported total income of Rs. 1060.8 crores during the period ended September 30, 2023 as compared to Rs.452.6 crores during the period ended September 30, 2022.
The company has posted net profit / (loss) of Rs.369 crores for the period ended September 30, 2023 as against net profit / (loss) of Rs.56.8 crores for the period ended September 30, 2022.
The company has reported EPS of Rs.20.60 for the period ended September 30, 2023 as compared to Rs.3.11 for the period ended September 30, 2022.
| Financials | Q2 FY2024 | Q2 FY2023 | % Change |
| Total Income | ₹ 1060.8 crs | ₹452.6 crs |  134.38% |
| Net Profit | ₹369 crs | ₹56.8 crs | 549.65% |
| EPS | ₹20.60 | ₹3.11 | 562.38% |
Financial Results (Half Year Ended FY2024) - YoY Comparison
The company has reported total income of Rs.2221 crores during the 6 Months period ended September 30, 2023 as compared to Rs.1371.5 crores during the 6 Months period ended September 30, 2022.
The company has posted net profit / (loss) of Rs.789.3 crores for the 6 Months period ended September 30, 2023 as against net profit / (loss) of Rs.377.2 crores for the 6 Months period ended September 30, 2022.
The company has reported EPS of Rs.43.88 for the 6 Months period ended September 30, 2023 as compared to Rs.20.66 for the 6 Months period ended September 30, 2022.
| Financials | Half Year Ended FY2024 | Half Year Ended FY2023 | % Change |
| Total Income | ₹2221 crs | ₹1371.5 crs | 61.94% |
| Net Profit | ₹789.3 crs | ₹377.2 crs | 109.25% |
| EPS | ₹43.88 | ₹20.66 | 112.39% |
Shares of Natco Pharma Limited was last trading in BSE at Rs. 793.80 as compared to the previous close of Rs. 793.55. The total number of shares traded during the day was 32249 in over 2304 trades.
The stock hit an intraday high of Rs. 799.95 and intraday low of 779.40. The net turnover during the day was Rs. 25427561.00.
